BioRelix Secures $2,558,096 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0467c7d8-a0f3-4ad7-bb50-c2e5b28658e4&Preview=1 -
Date
3/22/2012 -
Company Name
BioRelix -
Mailing Address
5 Science Park 401 Winchester Avenue New Haven, CT 06511 -
Company Description
BioRelix, Inc. is a market-driven company that discovers and develops antibiotics that target pathogens resistant to currently available drugs. BioRelix’ competitive advantage resides in the use of novel patented bacterial RNA targets called RiboSwitches that were identified by the laboratory of BioRelix’ founder, Dr. Ronald Breaker at Yale University. -
Website
http://www.biorelix.com -
Transaction Type
Debt -
Transaction Amount
$2,558,096 -
Transaction Round
Undisclosed -
Proceeds Purposes
Offering of promissory notes and warrants. Proceeds purposes were not disclosed. SEC regulatory filing. -
M&A Terms
-
Venture Investor
Undisclosed
